GlassScriptPhysician profile
Emily Green
NPI 1669009858
$3,796.85
in general payments reported to CMS, 2019-2025
38 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.95 · 2022: $1,646 · 2023: $743 · 2024: $254 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $627.31 | 2022-2025 | Krystexxa, Tavneos, Prolia |
| Abbvie INC. | $611.09 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $265.72 | 2022-2025 | Farxiga |
| Novo Nordisk INC | $261.59 | 2022-2025 | Rybelsus, Ozempic |
| Zimvie INC. | $221.81 | 2023 | |
| Sumitomo Pharma America, INC. | $195.95 | 2023-2025 | Orgovyx |
| Ardelyx, INC. | $167.46 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.99 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $108.80 | 2025 | |
| Glaxosmithkline, LLC. | $95.94 | 2022-2023 | Shingrix, Bexsero, Arexvy |
| Scpharmaceuticals INC. | $85.05 | 2025 | |
| Merck Sharp & Dohme LLC | $77.54 | 2022-2023 | Dificid |
| Lilly USA, LLC | $75.57 | 2022-2025 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $73.22 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.20 | 2022-2023 | Xifaxan |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.